PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30182439-0	2019	Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.	Celecoxib	0-9	fatty acid synthase	Mus musculus	101-105	
30182439-9	2019	In addition, celecoxib efficiently repressed the phosphor-Akt (Thr308)/fatty acid synthase (FASN) axis both in vivo and in vitro.	Celecoxib	13-22	fatty acid synthase	Mus musculus	71-90	
30182439-9	2019	In addition, celecoxib efficiently repressed the phosphor-Akt (Thr308)/fatty acid synthase (FASN) axis both in vivo and in vitro.	Celecoxib	13-22	fatty acid synthase	Mus musculus	92-96	
30182439-10	2019	Altogether, this study suggests that celecoxib exerts its antilipogenic efficacy by targeting a COX-2/AKT/FASN cascade, which contributes to its ability to delay hepatocarcinogenesis.	Celecoxib	37-46	fatty acid synthase	Mus musculus	106-110	
19159447-10	2009	Addition of celecoxib, a selective COX-2 inhibitor, significantly decreased PGE2 secretion (p < 0.05) versus control, and also significantly decreased FAS activity (p < 0.05).	Celecoxib	12-21	fatty acid synthase	Mus musculus	154-157	
19159447-11	2009	Unexpectedly, the combination of exogenous PGE2 and celecoxib further decreased the FAS activity compared to PGE2 alone or untreated controls.	Celecoxib	52-61	fatty acid synthase	Mus musculus	84-87